InvestorsHub Logo
Followers 24
Posts 1480
Boards Moderated 0
Alias Born 10/05/2015

Re: None

Thursday, 03/09/2017 1:16:17 PM

Thursday, March 09, 2017 1:16:17 PM

Post# of 461584
Neurotrope has a "properly designed trial"? A Ph 2b with efficacy as a primary endpoint that is only 3 months long for an Alzheimers trial. 3 months? Alzheimers is a neurodegenerative disease btw. If all Alzheimers trials ended at 3-6 months, donepezil woulda been declared the cure a long time ago. Neurotrope has now declared they're doubling down on 3 month trials, or rather tripling down (their Ph 2a tracked patients for 3 months after administering them just 1 IV treatment of the drug). If Ph 2b results looked good, they planned long time ago to do a 6 month Ph 3 pivotal trial. 6 months is even very short for a Ph 3 Alzheimers trial. But last summer they said if they do a Ph 3 trial, they're gonna shorten it from the planned 6 months down to just 3! For a Ph 3 Alzheimers trial. No joke. They said they need to shorten it to 3 months to rush it to market ASAP to help patients ASAP. Mmmkay. To my knowledge, none of Neurotrope's bryostatin trials have included any objective tests using biomarkers. In contrast, Anavex is employing P300 and erp testing.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News